June 3, 2022 News by Marta Figueiredo, PhD Lyvispah, Dissolvable Form of Baclofen, Now Available in US Lyvispah ā a dissolvable granular formulation of baclofen ā is now commercially availableĀ in the U.S. for adults and adolescents, 12 and older, with spasticity associated with multiple sclerosis (MS) and other spinal cord disorders. In people with MS, the strawberry-flavored formulation is particularly suitable to ease flexor…
September 8, 2020 News by Joana Carvalho, PhD Bafiertam, Oral Relapsing MS Therapy, Arrives in US Bafiertam (monomethyl fumarate), a bioequivalent of TecfideraĀ to treat relapsing forms of multiple sclerosis (MS), is now available to patients in the U.S. through a network of specialty pharmacies, Banner Life Sciences, the therapyās developer, announced. Banner previously stated that Bafiertam would arrive on the market…
May 5, 2020 News by Steve Bryson, PhD FDA Approves Bafiertam, Tecfidera Bioequivalent, for Relapsing MS The U.S. Food and Drug Administration (FDA) has given final approval toĀ Banner Life Sciencesā Bafiertam (monomethyl fumarate),Ā a bioequivalent alternative to Biogenās Tecfidera (dimethyl fumarate) to treat people with relapsing…
March 2, 2020 News by Ana Pena PhD #ACTRIMS2020 – Ofatumumab Self-injection Pen Equivalent to Prefilled Syringe, APLIOS Trial Shows Using a patient-friendly autoinjector pen to take monthly doses of ofatumumab ā an investigationalĀ B-cell therapy for relapsing multiple sclerosis (MS) ā is bioequivalent to delivering it via a prefilled syringe, and would allow self-administration of the treatment at home, a study shows. Equal effects…
January 4, 2019 News by Alberto Molano, PhD Bafiertam, a Bioequivalent of Tecfidera, Receives Tentative OK from FDA for RRMS Banner Life SciencesĀ has received tentative approval from the U.S. Food and Drug Administration (FDA) for its new drug application (NDA) for Bafiertam (monomethyl fumarate), a novel bioequivalent of Biogenās Tecfidera (dimethyl fumarate) for the treatment of relapsing-remitting multiple sclerosis (RRMS). Final approval is expected no later than…
June 20, 2017 News by Patricia Silva, PhD AXIM Obtains More Financing for Its Cannabinoid Therapies for MS and Bowel Diseases AXIM BiotechnologiesĀ has secured an additional $4 million in institutional financing to advance clinical trials of itsĀ cannabinoid therapies forĀ multiple sclerosis (MS) andĀ irritable bowel syndrome. Some of the trials involve a chewing-gum therapy delivery system.Ā The financing will let the company continue developing a patented chewing-gum-delivered therapy for pain andĀ spasticity. AXIM…